MONTREAL, June 22,
2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB:
VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a
Canadian pharmaceutical company, today announced that Ms.
Tamara Close and Mr. Didier Leconte have joined its Board of
Directors. Following the appointment of Ms. Close and Mr. Leconte,
Valeo's Board of Directors is now comprised of 8 Directors, 5 of
whom are independent.
"We are pleased to welcome Tamara and Didier to the Valeo Board
of Directors. Their extensive and diverse investment experience
brings valuable insight and perspective to our Board at a time when
we are experiencing rapid growth", said Richard MacKay, Chairman. "We look forward to
benefiting from their contribution and guidance as Valeo continues
to develop as a leading Canadian pharmaceutical company".
Ms. Close is a senior investment and Environmental, Social and
Governance (ESG) professional with over 25 years of experience in
capital markets, with roles spanning sell-side trading and
institutional sales to buy-side research, risk management and
strategy. She is the founder and managing partner of Close Group
Consulting, an independent, boutique ESG advisory firm
headquartered in Montreal, with
offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker
and regularly publishes ESG thought leadership and research.
Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from
McGill University and is a Chartered
Financial Analyst (CFA).
Mr. Didier Leconte is a
highly experienced investor and Canadian life sciences leader. He
has deep commercial experience in Canada and Québec's technology transfer
and investment arenas. With a strong dedication to the development
of Québec's and Canada's life
sciences industries, Didier served as Vice-president, Life Science
& Technology for Investissement Quebec and Vice-president Life
Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA,
Technology Management & Innovation from the Université du
Québec à Montréal, a certification in governance from Université
Laval and an engineering degree in
Material Sciences from École d'ingénieurs Sup Galilée, Institut
Galilée, Université Sorbonne Paris Nord.
About Valeo Pharma Inc.
Valeo Pharma is a fast-growing Canadian pharmaceutical company
dedicated to the commercialization of innovative prescription
products in Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.